<DOC>
	<DOCNO>NCT01596504</DOCNO>
	<brief_summary>Primary Objective : - To investigate effect repeat subcutaneous dos lixisenatide 20 μg daily ( QD ) compare liraglutide 1.2 mg QD 1.8 mg QD reduce post-prandial plasma glucose ( PPG ) assess area plasma glucose-concentration-time curve ( AUC ) standardize breakfast end 8-week treatment period participant type 2 diabetes mellitus ( T2DM ) adequately control insulin glargine ( ± metformin ) . Secondary Objectives : - To assess effect lixisenatide 20 μg QD compare liraglutide 1.2 QD 1.8 mg QD 8-week treatment period participant T2DM adequately control insulin glargine ( ± metformin ) : - Post-prandial C-peptide , glucagon appetite perception standardize breakfast , - Appetite perception standardize dinner , - Gastric empty standardize labelled test meal , - Fasting plasma glucose , 24-hour plasma glucose profile , - Glycosylated hemoglobin ( HbA1c ) , - Insulin glargine dose , - 7-point self monitor plasma glucose ( SMPG ) , - Body weight waist circumference , - 24-hour heart rate blood pressure , - To assess lixisenatide liraglutide safety tolerability add treatment insulin glargine ( ± metformin ) .</brief_summary>
	<brief_title>Pharmacodynamic Effects Lixisenatide Compared Liraglutide Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With Without Metformin</brief_title>
	<detailed_description>Up 2-week screening period - A run-in period 12 week maximum include forced titration insulin glargine 11 week 1 baseline pharmacodynamic assessment week - A 8-week treatment ( ) period ( ) Day 57 - Follow-up : 7 ±2 day last treatment day - Total study duration approximately 14 week 23 week</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Inclusion criterion : Participants T2DM diagnose least 1 year screen visit . Treatment neutral protamine hagedorn ( NPH ) insulin glargine least 3 month stable dose ( ±20 % ) least 10 IU/day ( least 2 month prior screen ) alone combine stable dose metformin without dipeptidyl peptidase 4 ( DPP4 ) inhibitor sulfonylurea . Glycosylated hemoglobin ( HbA1c ) ≥6.5 ≤9.5 % . Body mass index ( BMI ) 20 40 kg/m^2 . Exclusion criterion : Pregnant woman breastfeed woman . Clinically relevant history gastrointestinal disease associate prolonged nausea vomiting , include , limited , gastroparesis gastroesophageal reflux disease require medical treatment within 6 month prior time screen . Any previous treatment lixisenatide participation previous study lixisenatide ( AVE0010 ) , previous treatment liraglutide stop safety concern lack efficacy . Allergic reaction glucagonlike peptide1 ( GLP1 ) agonist past ( eg , exenatide ) metacresol . History unexplained pancreatitis , chronic pancreatitis , pancreatectomy , stomach/gastric surgery , inflammatory bowel disease . Personal family history medullary thyroid cancer ( MTC ) genetic condition predisposes MTC . The information intend contain consideration relevant participant 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>